Elixir, a pharmacy benefit manager owned by Rite Aid, announced that its specialty pharmacy, Elixir Specialty, was recently selected to be added to the limited distribution network of only 13 pharmacies nationwide to distribute the cancer drug Lenvima (lenvatinib).
Due to the complexity of specialty medications, they are often released as limited distribution drugs to an exclusive network of pharmacies that can demonstrate the ability to provide the highest clinical standards, including an understanding of the disease state and the ability to properly handle and store the medication, as well as provide patient monitoring, education, support and care, which are needed to optimize the treatment.
Lenvima, a kinase inhibitor developed by Eisai, is an oral capsule indicated for the treatment of thyroid, kidney, liver and endometrial cancers, some in combination with other drugs. Like most oncology treatments, there is a risk of drug toxicity and adverse events.
“Our clinical program proactively addresses and mitigates risk to avoid premature therapeutic discontinuation,” said Jordan Maddocks, director of clinical services and outcomes at Elixir Specialty. “This allows members to continue with their treatment to get the most out of their therapy, improving their whole health.”
McKesson opens registration for in-person ideaShare 2022
McKesson ideaShare 2022 is returning as a live event from July 7 to 10 in Washington D.C.
By registering early, attendees may be eligible to earn a rebate of 2% of total OneStop Generics purchases of up to $4,000.
McKesson touts ideaShare as the nation’s premier community pharmacy event that empowers current and future independent pharmacists to foster deeper connections, discover ways to innovate and thrive, and strengthen their collective voice. Featuring a range of large group sessions and smaller roundtable discussions to an energetic show floor, the meeting has been reimagined to give independent pharmacists and their staff a customized experience focused on building a brighter future for the independent pharmacy industry — together.
Lightlife is continuing to expand upon its plant-based food options by debuting two new takes on traditional chicken.
Its plant-based chicken breasts and plant-based chicken strips are made with simple ingredients that mimic the texture and flavor of chicken, the Chicago-based company said.
“Lightlife Plant-Based Chicken Breasts and Strips deliver a chicken-like eating experience and versatility that is unmatched," said Jitendra Sagili, chief research and development and food technology officer of Greenleaf Foods, SPC. "These products reflect our vision of relentlessly evolving the product designs, utilizing ingredient technologies delivering on consumers’ expectations for taste, color and texture.”
The plant-based chicken breasts and chicken strips offer between 9 to 6 g of protein per serving, and are made using the brand’s high-moisture extrusion technology to deliver a juice texture similar to the traditional chicken experience.
Made with pea protein, both plant-based chicken offerings are Non-GMO Project Verified, vegan certified and do not contain artificial flavors.
“Plant-based chicken is the No. 2 selling plant-based protein segment based on dollar sales, with a category size of $308 million, creating a significant opportunity to drive the segment forward and bring in new consumers,” said Adam Grogan, president of Greenleaf Foods, SPC. “We’re excited to invite consumers to experiment with Lightlife plant-based chicken breasts and strips across a variety of hot and cold applications.”
Consumers can find Lightlife’s plant-based chicken breasts and chicken strips at Publix and Whole Foods Market locations nationwide.
Day One CBD sparkling water has teamed up with LA Distributing Company to manage and expand distribution of Day One across Los Angeles, Orange, Riverside, San Bernardino, Ventura and Santa Barbara, Calif.
“Day One is not a new face to the CBD category,” said Richard Media, founder and CEO of LA Distributing Company. “The brand resurrected at the opportune time with the passing of AB45 in 2021; we anticipate mass adoption from all channels of trade in 2022. The branding is simple and straightforward, as they are a premium enhanced sparkling water. The dosage is perfect with the most competitive pricing economics in the market.”
The partnership accentuates Day One’s commitment to the California market.
“This is a recipe for category disruption, and we expect them to quickly dominate in our footprint,” Media said. “We are excited to have them part of our portfolio and look forward to seeing them become a national brand.”
The distribution announcement comes on the heels of Day One being recently named the exclusive and “official CBD partner of USA Pickleball” for a three-year term.
“It’s exciting to align Day One with LA Distributing Company, a leading beverage distributor in the LA market,” said Chris Clifford, founder and CEO of Day One Beverages. “It’s no secret that Southern California, and Los Angeles County in particular, has a great concentration of consumers seeking healthier-for-you beverage alternatives, and we couldn’t be more excited to be introducing Day One in this key market alongside the best in the business.”
Fresenius Kabi intros calcium gluconate in freeflex bags
Fresenius Kabi is bringing out two new presentations of calcium gluconate in sodium chloride injection in the company’s proprietary, ready-to-administer freeflex containers. Calcium gluconate in sodium chloride injection is a form of calcium indicated for pediatric and adult patients in the treatment of acute symptomatic hypocalcemia.
Fresenius Kabi said that it now has the broadest portfolio of calcium gluconate injection products available from any manufacturer in the United States.
"Our new premixed calcium gluconate freeflex offerings will help meet the growing demand for ready-to-administer medicines in the U.S.,” said John Ducker, president and CEO of Fresenius Kabi USA. “By offering calcium gluconate injection in two delivery systems, Fresenius Kabi can provide healthcare professionals with more flexibility and choice to best serve patient needs.”
Noting that freeflex is an innovative non-PVC and non-DEHP, multilayer polyolefin film bag designed for infusion solutions that has been marketed globally since 2005 and in the U.S. since 2008, the company said that freeflex promotes the safety and convenience of infusion therapy in a ready-to-administer presentation.
Genexa is rolling out Acetaminophen Extra Strength and Acetaminophen PM caplets, which it is touting as clean products that contain the same active ingredients and dosages of current category leaders but without artificial dyes, synthetic fillers and other artificial preservatives.
“Now consumers do not have to choose between efficacy and clean ingredients. Our mission of putting people over everything means providing options to those who care about knowing the ingredients in what they are taking,” CEO and co-founder David Johnson said. “We’re bringing options to people’s medicine cabinets they have never had before because we believe that it's time to evolve the decades-old formulas in our everyday medicines without compromising on efficacy.”
The company also shared that Genexa Acetaminophen Extra Strength has 500 mg of the pain reliever acetaminophen, contains the same dosage found in Extra Strength Tylenol, and Genexa Acetaminophen PM has 500mg of the pain reliever acetaminophen and 25 mg of diphenhydramine HCl, has the same dosage found in Tylenol PM.
“In my experience, more and more frequently I am seeing that my patients are doing their best to avoid eating foods that contain artificial additives like dyes, preservatives and assorted other fillers. They have shared with me that they long for medicines that are effective but not full of artificial fillers. I am so happy to finally have a medicine I can recommend to them,” Genexa Medical Advisor Taz Bhatia, a board-certified integrative medicine physician and wellness expert, and founder of CentreSpring MD, said. “This groundbreaking product launch from Genexa is an exciting moment for both the industry and for patients across the country, finally delivering a real choice for people pursuing clean living who are in need of a pain reliver.”
“Genexa’s product launches offer new innovation and a forward-thinking approach that will help serve as a catalyst to the entire consumer pharmaceutical industry,” Brian Perkins, chairman of Genexa said. “Consumers deserve options and transparency in their medicine and Genexa is delivering on this need."
Currently, Walmart is the exclusive mass retailer for Genexa’s acetaminophen products, but the SKUs can also be found at CVS Pharmacy, Amazon.com, and Genexa.com among others.